You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Tempest reported Q3 revenue of $411.5 million, up 23% year-over-year, and $25.6 million adjusted EBITDA; it raised 2026 guidance to $1.60 to $1.605 billion while maintaining approximately $65 million adjusted EBITDA and cleared regulatory review of its Personalis acquisition.
Tempus AI posted $411.5 million for the three months ended September 30, 2026, up from $334.2 million, and $14.9 million net loss versus $80.0 million. It expects its $1.5 billion Personalis acquisition to close in the fourth quarter of 2026.
Tempus AI, Inc. reported third-quarter revenue of $411.5 million, up 23%, and Adjusted EBITDA of $25.6 million. It raised full year 2026 revenue guidance to $1.60 to $1.605 billion and expects Adjusted EBITDA of ~$65 million.
Tempus AI, Inc. entered agreements with Bristol-Myers Squibb Company and Pathos AI, Inc. providing aggregate cash payments of $192.5 million over approximately five years: $137.5 million for oncology data and related services and $55 million for neurology data and an agentic tool.
Tempus AI, Inc. proposes acquiring Personalis, Inc. under a merger agreement, with consideration of 0.3356 Tempus shares if Tempus stock is $48.42 or less, otherwise $16.25 divided by its stock price.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $5.21M | Six Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP EBITDA $38.32M
+$2.86M Losses from equity method investments
-$97.4M Fair value changes
+$54.12M Stock-based compensation expense
+$1.49M Employer payroll tax related to stock-based compensation
+$990K Acquisition related expenses
-$3.99M Amortization of technology license
+$0K Franchise taxes related to IPO
+$11.64M Loss on debt extinguishment
= Adjusted EBITDA $8.04M
|
|||
| Hereditary tests | 141,500 | the three months ended June 30, 2026 filing | — |
| Molecular residual disease (MRD) volume | 9,000 | Q2 2026 | — |
| Oncology tests | 96,500 | the three months ended June 30, 2026 filing | — |
| Oncology volume growth | 31% | Q2 2026 | — |
| revenue from related parties | $22M | the three months ended June 30, 2026 filing | — |
| Volume of tests | 238,000 | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TEM
this stock
Tempus AI, Inc.
|
$13.06B | +21.3% | +83.4% | — | 13.5% |
|
VEEV
Veeva Systems Inc
|
$48.82B | +35.1% | +28.1% | 49.4 | 2.4% |
|
PMDIY
Pro Medicus Ltd.
|
$14.81B | -14.6% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$14.17B | +90.1% | +28.2% | 38.7 | 5.8% |
|
HNGE
Hinge Health, Inc.
|
$9.38B | +148.4% | +50.6% | 56.3 | 6.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Tempus AI posted $411.5 million for the three months ended September 30, 2026, up from $334.2 million, and $14.9 million net loss versus $80.0 million. It expects its $1.5 billion Personalis acquisition to close in the fourth quarter of 2026.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TEM | -5.9% | +10.6% | +53.5% | -0.9% | +21.3% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -8.4% | +11.8% | +53.0% | -0.7% | +10.6% |
